Views & Analysis
iStock 481032756_169

CAR-Ts dominated the agenda at ASH 2017

The American Society for Hematology congress was dominated by CAR-T therapies – their potential new uses, how to manage safety issues and bring these costly cellular treatments to patients.

Views & Analysis
blood_cells1 1024x576

ASH 2017: CAR-T therapy and beyond

As the American Society of Hematology’s 2017 congress approaches, there’s plenty to be excited about – not just in blood cancer, but in previously overlooked diseases such as sickle cell anaemi